Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
|Articles|February 1, 2013
Dermatology Times, Digital Edition, February 2013
Derms take 'hammering' with cuts to three codes New tanning group targets UV 'myths' Clinical Dermatology : Pneumocystis pneumonia prophylaxis may be required in immunosuppressed patients Special Report : Identifying type of hair loss allows for appropriate treatment selections Cosmetic Dermatology : Skin poration is an old concept that is now being for placing hyaluronic acid into the skin Cutaneous Oncology : Despite research, relationship between serum vitamin D levels, melanoma remains uncertain Business of Dermatology : Electronic prescribing creates communication bridge between patient, physician and pharmacist
Advertisement
Advertisement
Related to this article
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.
Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
Advertisement
Advertisement
Trending on Dermatology Times
1
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
2
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
3
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
4
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
5